Replies to post #18332 on Elite Pharmaceuticals Inc (ELTP)

[lasers]

Steges

ref

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=76338403

In my post "(1)" is For the Pharmacological Formulation Patent Grant 8,182,836


http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,182,836.PN.&OS=PN/8,182,836&RS=PN/8,182,836

Elaborating further

"(1)The 1st Patent Grant 8,182,836 is for the Pharmacological Formulation of the polymer ( Eudragit 30D/40D)that sequesters and prevents the antagonist from leaking into the body before 3 days."

This Patent Grant assures the correct antagonist delivery when ELI-216 is taken by a patient through the oral ROA as prescribed by the physician. The antagonist will NOT be prematurely leaked and that this feature is expected to be intact for 3 days inside the patient. After 3 days it is expected that the antagonist beads will be passed harmlessly by the patient.


####

"(2)The current 2nd Patent Application 12/640,344 is the 2-bead manufacturing technology that makes (1) work when the agonist opioid and the antagonist opioid are combined and taken together"

This Patent Application 12/640,344 is the unique 2-bead manufacturing technology invented by Elite to assure the correct intact DELIVERY of the agonist and antagonist beads inside the human body. Namely that (i) the agonist CR polymer 12 hrs or 24 hrs releases the opioid correctly time wise as designed and (ii) the antagonist sequestered membrane polymer does not leak prematurely but remains intact unbroken during the 3 days and then passes harmlessly out.